What if you could shorten the time it takes to activate apheresis and cell collection sites to begin collecting starting material for your cell or gene therapy and simultaneously create efficiencies for those sites?
A standardized quality system audit (QSA) program, like the Quality System Audit Program (QSAP) offered by Be The Match BioTherapies®, helps accelerate patient access to life-saving cell and gene therapies while ensuring quality compliance at apheresis and cell collection centers.
With QSAP, one organization audits each center one time over an established timeframe, such as every two years. Cell and gene therapy companies license the audit results from the auditing organization, alleviating the necessity for multiple companies to conduct individual, yet similar, audits at the same sites.
Therapy developers can more rapidly move sites from qualification to activation. And, collection centers can spend less time on audit activities and more time collecting high-quality starting material for therapy manufacturing and delivery to patients.
The result? Patients get access to new cell and gene therapies sooner.
Download our white paper, authored by Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program; Amy Hines, RN, BSN, director, Collection Experience, Be The Match BioTherapies and Richard Smith, consultant, Be The Match BioTherapies, to explore the challenges of the current quality system audit environment and the benefits that a standard QSA program offers cell and gene therapy companies, apheresis and collection centers, and labs.